{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:45Z","timestamp":1793467605516,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00277-020-04311-z","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T21:02:40Z","timestamp":1603227760000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-dose ruxolitinib shows effective in treating myelofibrosis"],"prefix":"10.1007","volume":"100","author":[{"given":"Yunfan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-7585","authenticated-orcid":false,"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"issue":"4","key":"4311_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","volume":"158","author":"JT Reilly","year":"2012","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michaeel NG, Gilleece MH, Hall GW, Knapper S, Mead A, Mesa RA, Sekhar M, Wilkins B, Harrison CN (2012) Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 158(4):453\u2013471. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09179.x","journal-title":"Br J Haematol"},{"issue":"1","key":"4311_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","volume":"35","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP (2011) MPN-associated myelofibrosis (MPN-MF). Leuk Res 35(1):12\u201313. https:\/\/doi.org\/10.1016\/j.leukres.2010.07.019","journal-title":"Leuk Res"},{"key":"4311_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL (2009) Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 60:233\u2013245. https:\/\/doi.org\/10.1146\/annurev.med.60.041707.160528","journal-title":"Annu Rev Med"},{"issue":"9 Suppl 22","key":"4311_CR4","first-page":"1","volume":"9","author":"SA Gregory","year":"2011","unstructured":"Gregory SA, Mesa RA, Hoffman R, Shammo JM (2011) Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol 9(9 Suppl 22):1\u201316","journal-title":"Clin Adv Hematol Oncol"},{"issue":"13","key":"4311_CR5","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"2","key":"4311_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","volume":"91","author":"F Delhommeau","year":"2010","unstructured":"Delhommeau F, Jeziorowska D, Marzac C, Casadevall N (2010) Molecular aspects of myeloproliferative neoplasms. Int J Hematol 91(2):165\u2013173. https:\/\/doi.org\/10.1007\/s12185-010-0530-z","journal-title":"Int J Hematol"},{"issue":"26","key":"4311_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.2174\/092986712803251511","volume":"19","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Mughal TI, Verstovsek S (2012) Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 19(26):4399\u20134413. https:\/\/doi.org\/10.2174\/092986712803251511","journal-title":"Curr Med Chem"},{"issue":"9","key":"4311_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"4311_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"25","key":"4311_CR10","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u20134053. https:\/\/doi.org\/10.1182\/blood-2013-02-485888","journal-title":"Blood"},{"issue":"1","key":"4311_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10(1):156. https:\/\/doi.org\/10.1186\/s13045-017-0527-7","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4311_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S (2018) Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol 11(1):42. https:\/\/doi.org\/10.1186\/s13045-018-0585-5","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4311_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood.V95.1.19","volume":"95","author":"AC Ward","year":"2000","unstructured":"Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95(1):19\u201329","journal-title":"Blood"},{"key":"4311_CR14","unstructured":"Jakafi\u00ae IC (2013) [prescribing information]. Available from: http:\/\/www.incyte.com\/sites\/default\/files\/Jakafi_PI.pdf. Accessed Sept 24, 2013."},{"key":"4311_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/ott.s53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13\u201321. https:\/\/doi.org\/10.2147\/ott.s53348","journal-title":"Onco Targets Ther"},{"issue":"20","key":"4311_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"33","key":"4311_CR17","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RA Mesa","year":"2012","unstructured":"Mesa RA, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103. https:\/\/doi.org\/10.1200\/JCO.2012.42.3863","journal-title":"J Clin Oncol"},{"issue":"5","key":"4311_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"4","key":"4311_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2016.283","volume":"31","author":"M Marchetti","year":"2017","unstructured":"Marchetti M, Barosi G, Cervantes F, Birgegard G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kroger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T (2017) Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia 31(4):882\u2013888. https:\/\/doi.org\/10.1038\/leu.2016.283","journal-title":"Leukemia"},{"issue":"1","key":"4311_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12185-017-2332-z","volume":"107","author":"K Kirito","year":"2018","unstructured":"Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N (2018) Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. Int J Hematol 107(1):92\u201397. https:\/\/doi.org\/10.1007\/s12185-017-2332-z","journal-title":"Int J Hematol"},{"issue":"45","key":"4311_CR21","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073\u201379086. https:\/\/doi.org\/10.18632\/oncotarget.18674","journal-title":"Oncotarget"},{"key":"4311_CR22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, Garc\u00eda-Hern\u00e1ndez C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, H\u00e4nel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM (2020) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 189:888\u2013903. https:\/\/doi.org\/10.1111\/bjh.16462","journal-title":"Br J Haematol."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04311-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04311-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04311-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T11:50:45Z","timestamp":1634730645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04311-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4311"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04311-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"16 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}